RSV: A New Era in Prevention

Ami Patel, PhD, provides insights on both technologies and how her research center, the Wistar Institute, is involved in DNA vaccine and monoclonal antibody research.

Syra Madad, DHSC, MSc, MCP, CHEP, outlines early surveillance systems and diagnostic innovations for enhancing pandemic management and response.

Pfizer's Phase 3 MONeT trial shows that Abrysvo is safe and effective in producing strong immune responses against RSV in immunocompromised adults.

In this week’s edition of MMWR, the Centers for Disease Control and Prevention reported on the vaccines’ safety profile for each of the FDA approved immunizations and rationale for the recommended age groups.

Results demonstrate high safety and reduced need for oxygen supplementation in patients with COVID-19 viral pneumonia.

Providing nirsevimab (Beyfortus) to all newborns and high-risk infants during the 2024-2025 RSV season represents an advancement in protecting infant health.

Merck’s antibody, clesrovimab (MK-1654), is designed to protect infants against medically attended lower respiratory infections (MALRI) caused by RSV.

Participants using nasal sprays experienced significantly shorter illness durations and reduced antibiotic usage compared to those receiving usual care.

A clinical stage company, NanoViricides, is moving forward with their investigational drug, NV-387, into phase 2 clinical trials to examine treatment for RSV, influenza, COVID-19.

Despite initial concerns about vaccine safety, the study of nearly 3000 patients found no elevated risk of preterm birth associated with prenatal vaccination.

The federal agency says everyone 75 years of age and older should receive the RSV vaccine.

With the recent phase 3 data results of the Moderna COVID-19-influenza combination vaccine, the company is working towards regulatory approval and opens the door to possible protection against multiple viruses with less immunizations.

Study reveals an increase in hospital admissions and the need for advanced respiratory support, particularly among older, healthier children.

A study points to inpatients who were 50 years and older with the respiratory illness suffering from heart-related complications with the largest number of them having acute heart failure. 

In the fourth and final episode, the clinicians speak of the need for greater uptake of the RSV vaccines, overcoming an "RSV identity crisis," and the potential ancillary benefit of reducing bacterial infections.

Our experts discuss the potential subgroups who might benefit from the vaccines and their safety profiles.

In part 2 of a 4-part series, clinicians discuss the efficacy, and the mechanism of action of the approved RSV vaccines, including the newly approved Moderna vaccine, mRNA 1345 (mRESVIA).

This is the first in a series of discussions between medical peers around RSV vaccines and specifically the newly approved Moderna RSV vaccine for seniors.

The federal agency’s decision expands the vaccine’s eligibility to people 50 years of age and older, making it the first one for this age group.

Ongoing surveillance from the CDC and FDA will continue to evaluate the risk of Guillan-Barré syndrome to guide further ACIP recommendations.

The company’s mRNA 1345 vaccine was given the nod by the federal agency and is indicated for seniors for the prevention of RSV-associated lower respiratory tract disease (RSV-LRTD).

The program allows participants to reserve doses and be eligible for priority shipping, among other benefits.

The federal agency said that due to administrative constraints, they will not complete the review of mRNA-1345 by the PDUFA date of May 12.

The investigational vaccine, mRNA-1345, developed for seniors has its FDA PDUFA date in a few days.

In a new real-world study, Sanofi and AstraZeneca’s nirsevimab-alip (Beyfortus) demonstrated high efficacy against respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD).

FDA-approves mpox vaccine, FDA grants EUA for at-home multiplex papid test, FDA grants PDUFA for GSK 5-in-1 meningococcal vaccine, and more this month from the FDA.

The study findings imply newly available prevention strategies for which older children—ages 2 to 5 years—are not currently eligible should be prioritized.

The company is going to submit their data to the FDA to seek approval for people within this age group.